[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK3395354T3 - Plasminogen til anvendelse i behandling af diabetisk nefropati - Google Patents

Plasminogen til anvendelse i behandling af diabetisk nefropati Download PDF

Info

Publication number
DK3395354T3
DK3395354T3 DK16874925.7T DK16874925T DK3395354T3 DK 3395354 T3 DK3395354 T3 DK 3395354T3 DK 16874925 T DK16874925 T DK 16874925T DK 3395354 T3 DK3395354 T3 DK 3395354T3
Authority
DK
Denmark
Prior art keywords
plasminogen
treatment
diabetic nephropathy
nephropathy
diabetic
Prior art date
Application number
DK16874925.7T
Other languages
English (en)
Inventor
Jinan Li
Original Assignee
Talengen Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talengen Int Ltd filed Critical Talengen Int Ltd
Application granted granted Critical
Publication of DK3395354T3 publication Critical patent/DK3395354T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49Urokinase; Tissue plasminogen activator
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • A61K38/484Plasmin (3.4.21.7)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
DK16874925.7T 2015-12-18 2016-12-16 Plasminogen til anvendelse i behandling af diabetisk nefropati DK3395354T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015097944 2015-12-18
PCT/CN2016/110450 WO2017101868A1 (zh) 2015-12-18 2016-12-16 一种预防和治疗糖尿病肾病的方法

Publications (1)

Publication Number Publication Date
DK3395354T3 true DK3395354T3 (da) 2024-06-03

Family

ID=59055777

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16874925.7T DK3395354T3 (da) 2015-12-18 2016-12-16 Plasminogen til anvendelse i behandling af diabetisk nefropati

Country Status (9)

Country Link
US (1) US11090372B2 (da)
EP (1) EP3395354B1 (da)
JP (1) JP6682008B2 (da)
CN (1) CN108778307A (da)
CA (1) CA3008686C (da)
DK (1) DK3395354T3 (da)
ES (1) ES2985007T3 (da)
TW (1) TWI725092B (da)
WO (1) WO2017101868A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069567A (zh) 2015-12-18 2018-12-21 泰伦基国际有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
WO2017101872A1 (zh) 2015-12-18 2017-06-22 深圳瑞健生命科学研究院有限公司 一种用于预防和治疗宫颈糜烂的方法
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
CA3008691A1 (en) 2015-12-18 2017-06-22 Talengen International Limited Method for preventing or treating diabetic retinopathy
US11007253B2 (en) 2015-12-18 2021-05-18 Talengen International Limited Method for preventing or treating radiation and chemical damage
CA3008185C (en) 2015-12-18 2024-01-16 Talengen International Limited Method for prevention or treatment of acute and chronic thrombosis
CA3047175A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method for mitigating heart disease
CA3047176C (en) 2016-12-15 2021-11-30 Talengen International Limited Use of plasminogen for promoting secretion of insulin in treatment of diabetes
WO2018107687A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗高脂血症的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
WO2018233604A1 (zh) 2017-06-19 2018-12-27 泰伦基国际有限公司 一种调控glp-1/glp-1r的方法和药物
CA3167202A1 (en) * 2020-02-06 2021-08-12 Jinan Li Method and drug for preventing and treating multiple sclerosis
JP2023521530A (ja) * 2020-02-11 2023-05-25 タレンゲン インターナショナル リミテッド ウイルス性肺炎を治療する方法及び薬剤
CN115551534A (zh) * 2020-02-26 2022-12-30 泰伦基国际有限公司 一种预防和治疗血压异常病症的方法和药物
CN114073526A (zh) * 2020-08-21 2022-02-22 上海中医药大学附属曙光医院 一种基于磁共振弹性成像和血清学检查的肾纤维化评估方法

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ307044A (en) 1995-04-26 2002-03-01 Childrens Medical Center Angiostatin fragments with antiangiogenic activity
EP1001985A1 (en) 1997-06-26 2000-05-24 Karolinska Innovations AB Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
ES2276536T3 (es) 1998-09-29 2007-06-16 LEUVEN RESEARCH & DEVELOPMENT VZW Uso de compuestos que reducen las alfas2-antiplasminas in vivo para la preparacion de una composicion para el tratamiento del ictus isquemico.
WO2000044391A2 (en) 1999-01-28 2000-08-03 The Children's Medical Center Corporation Plasminogen kringle 4 region fragments and methods of use
US6899877B2 (en) 1999-03-09 2005-05-31 Minu, L.L.C. Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
EP1227833A1 (en) 1999-10-07 2002-08-07 Human Genome Sciences, Inc. Plasminogen-like polynucleotides, polypeptides, and antibodies
TWI240723B (en) 2001-06-20 2005-10-01 Wyeth Corp Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7067492B2 (en) 2001-09-06 2006-06-27 Omnio Ab Method of promoting healing of a tympanic membrane perforation
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US7202066B2 (en) 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
WO2003066842A2 (de) 2002-02-06 2003-08-14 Trommsdorff Gmbh & Co. Kg Arzneimittel Verfahren zur herstellung von rekombinanten proteinen in mikroorganismen
US6787135B2 (en) 2002-03-13 2004-09-07 William Beaumont Hospital Modification of vitreal matrix metalloproteinase activity
WO2004039956A2 (en) * 2002-10-29 2004-05-13 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB0228409D0 (en) 2002-12-06 2003-01-08 Thromb X Nv Pharmacological vitreolysis
CN1451746A (zh) 2003-03-20 2003-10-29 广州市启源生物科技有限公司 人纤溶酶原Kringle 5缺失突变重组多肽
US20050250694A1 (en) 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
CN1946352A (zh) 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
MX2007002177A (es) 2004-08-23 2007-04-02 Wyeth Corp Acidos de pirrolo-naftilo como inhibidores de pai-1.
CN101039936A (zh) 2004-08-23 2007-09-19 惠氏公司 作为i-型纤溶酶原激活剂抑制剂(pai-1)调节剂用于治疗血栓形成和心血管疾病的唑基-萘基酸
EP2269623A1 (en) 2005-04-29 2011-01-05 The Regents of The University of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CN101227918A (zh) 2005-04-29 2008-07-23 加州大学评议会 治疗以炎症反应为特征的病理的肽和肽模拟物
US20060257391A1 (en) 2005-05-11 2006-11-16 Bausch & Lomb Incorporated Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
CN101263115A (zh) 2005-08-17 2008-09-10 惠氏公司 经取代吲哚和其用途
WO2007051314A1 (en) 2005-11-07 2007-05-10 American Diagnostica Inc. Curcuminoid compounds for inhibiting plasminogen activator inhibitor-1
CN100529085C (zh) 2005-12-30 2009-08-19 上海新生源医药研究有限公司 重组人纤溶酶原Kringle 5(hk5)生产方法
CN101002888A (zh) 2006-01-16 2007-07-25 陈维森 复方糖尿康
US20070196350A1 (en) 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
MX2009002226A (es) * 2006-08-28 2009-09-07 Omnio Healer Ab Candidatos contra infeccion.
WO2009054439A1 (ja) 2007-10-23 2009-04-30 Institute Of Medicinal Molecular Design, Inc. Pai-1産生抑制剤
KR101529743B1 (ko) 2007-11-29 2015-06-17 그리폴스 테라퓨틱스 인코포레이티드 재조합적으로 변형된 플라스민
JP2009196927A (ja) 2008-02-21 2009-09-03 Chemo Sero Therapeut Res Inst 血管障害に起因する網膜障害の進展阻害または治療剤
WO2011139973A2 (en) 2010-05-03 2011-11-10 Abbott Laboratories Methods of inhibiting fibrosis using anti-pai-1 antibodies
CN102250210B (zh) 2010-05-21 2014-05-28 厦门大学 人纤溶酶原Kringle 5短肽、其药物组合物、用途和编码该种短肽的多核苷酸
CN102121023B (zh) 2010-12-22 2012-07-04 中山大学 突变型人纤溶酶原kringle5及其制备方法及应用
BR112013017172A2 (pt) * 2011-01-05 2016-10-11 Thrombogenics Nv variantes de plasminogênio e plasmina
CN102154253A (zh) 2011-01-06 2011-08-17 郑州大学 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
KR20140064841A (ko) 2011-08-12 2014-05-28 쓰롬보제닉스 엔.브이. 플라스미노겐 변이체 및 플라스민 변이체
DK2914575T3 (da) 2012-10-31 2021-01-18 Univ Michigan Regents Plasminogen-aktivator-1-inhibitorer og fremgangsmåder til anvendelse deraf
US9079739B2 (en) 2012-11-02 2015-07-14 The Procter & Gamble Company Apparatus for controlling the nip force/pressure between two rotating cylinders
TW201734054A (zh) 2013-08-13 2017-10-01 賽諾菲公司 胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途
SG10201710013RA (en) 2013-08-13 2018-01-30 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
CN104789544B (zh) 2014-01-16 2019-11-26 中国科学院福建物质结构研究所 重组pai-1抑制剂、包含其的组合物及其用于治疗和检测用途
KR102692851B1 (ko) 2014-12-19 2024-08-06 프로메틱 바이오 테라퓨틱스 인코포레이티드 플라스미노겐을 포함하는 약학 조성물 및 이의 용도
TWI801331B (zh) 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
EP3395354B1 (en) 2015-12-18 2024-05-22 Talengen International Limited Plasminogen for use in treating diabetic nephropathy
CA3008691A1 (en) * 2015-12-18 2017-06-22 Talengen International Limited Method for preventing or treating diabetic retinopathy
CA3008185C (en) * 2015-12-18 2024-01-16 Talengen International Limited Method for prevention or treatment of acute and chronic thrombosis
CN109069567A (zh) 2015-12-18 2018-12-21 泰伦基国际有限公司 一种预防或治疗糖尿病性神经损伤及其相关病症的方法
CA3047176C (en) 2016-12-15 2021-11-30 Talengen International Limited Use of plasminogen for promoting secretion of insulin in treatment of diabetes

Also Published As

Publication number Publication date
EP3395354A1 (en) 2018-10-31
JP2019500424A (ja) 2019-01-10
WO2017101868A1 (zh) 2017-06-22
US20190015485A1 (en) 2019-01-17
CA3008686A1 (en) 2017-06-22
EP3395354B1 (en) 2024-05-22
CN108778307A (zh) 2018-11-09
CA3008686C (en) 2023-03-14
US11090372B2 (en) 2021-08-17
EP3395354A4 (en) 2019-06-12
TWI725092B (zh) 2021-04-21
TW201722466A (zh) 2017-07-01
ES2985007T3 (es) 2024-10-31
JP6682008B2 (ja) 2020-04-15

Similar Documents

Publication Publication Date Title
DK3395354T3 (da) Plasminogen til anvendelse i behandling af diabetisk nefropati
CY2021029I2 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
DK3391902T3 (da) Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati
DK3191144T3 (da) Medicinsk forbinding
DK3134530T3 (da) Behandling af hyperbilirubinæmi
DK3882250T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
DK3778595T3 (da) Pancreatitisbehandling
DK3197472T3 (da) Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri
DK3185957T3 (da) Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3307296T3 (da) Timp2 til anvendelse til behandling af aldringsassocierede tilstande
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3524255T3 (da) Sammensætning til behandling af acne
DK3231444T3 (da) Ny behandling
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3556383T5 (da) Plasminogen til anvendelse ved behandling af diabetes
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3456330T3 (da) Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
DK3204038T3 (da) Sammensætninger omfattende amylase til anvendelse i behandlingen af pruritus
DK4119569T3 (da) Konjugerede antisense-forbindelser til anvendelse i behandling
DK2994157T3 (da) Tafa4-forbindelser og anvendelser deraf til behandling af smerte